Systemic lupus erythematosus (SLE) is a complex autoimmune disease which involves several organs. CD26 is a multifunctional molecule that has an extracellular domain with dipeptidyl peptidase IV activity which digests crucial inflammatory molecules. CD26 plays an important role in T-cell activation and enhances immune responses. This study was carried out to evaluate the level of CD26 gene expression in SLE patients. Forty-six SLE patients and 44 healthy controls voluntarily participated in this study. Based on the SLE disease activity index (SLEDAI), the patients were divided into two subgroups, those with active disease (n=24) and those with inactive disease (n=22). Patients were also subgrouped according to renal involvement, as those with lupus nephritis (n=17) and those without lupus nephritis (n=29). Their CD26 mRNA levels in peripheral blood cells were analyzed by quantitative RT-PCR. CD26 mRNA expression increased 3.6-fold in SLE patients in comparison with the controls (p<0.0001). No difference was found in the level of CD26 mRNA among the subgroups of the SLE patients with the active or inactive form of the disease (p>0.05). Although CD26 mRNA expression in patients with lupus nephritis was 2.76-fold higher than those without nephritis, the difference was not statistically significant (p>0.05). CD26 gene expression in peripheral blood cells of SLE patients significantly increased over that of the controls. This increase was not affected by the disease activity nor did it show any significant correlation with complications in organs.
Background: We evaluated role(s) of miR-202 in glioma cell lines, its effect on ROCK1 expression, and also evaluation of apoptosis and migration of human glioma cell line after transfection with miR-202 mimics and inhibitors. Material and methods: The cell lines were transfected with mimic, inhibitor and NC of miR-202. Reverse transcription polymerase chain reaction (RT-PCR) was conducted to evaluate the expression of miR‐202 and ROCK1 . Western blot was performed to detect the protein level of ROCK1. Furthermore, MTT and wound healing assay were performed to evaluate the effects of miR-202 on apoptosis and migration of human glioma cell line, respectively. Results: miR-202 showed a significantly decrease in human glioma cell lines, compared with the NHA cell line (P<0.05). The ROCK1 expression was significantly upregulated in glioma cell lines, compared with the NHA cell line ( P <0.05). Furthermore, a negative correlation was observed between expression of ROCK1 and miR-202 ( P =0.01, r=-0.426). The mRNA and protein levels of ROCK1 were decreased in U87 cell line in miR-202 mimics group, compared with mimic NC group (P<0.05). In addition, apoptosis was significantly increased in miR-202 mimics, compared with the NC group in U87 cell line at 72 and 96 h (P<0.05). Furthermore, invasion showed a significant decrease in miR-202 mimic group, compared with U87 cell line at 24 and 48 h (P<0.05). Conclusions: The miR-202 could serve as a tumour-suppressor miRNA in glioma. Therefore, targeting ROCK1 by miR-202 may increase improve disease outcome and could be considered as a potential therapeutic target for glioma patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.